Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 yearsʹ adjuvant treatment for breast cancer

The standard adjuvant endocrine treatment for postmenopausal women with hormone-receptor-positive localised breast cancer is 5 years of tamoxifen, but recurrences and side-effects restrict its usefulness. The aromatase inhibitor anastrozole was compared w